Comparison of Oncotype DX Recurrence Score by Histologic Types of Breast Carcinoma

Bomeisl, Philip; Thompson, Cheryl L.; Harris, Lyndsay N.; Gilmore, Hannah

doi:10.5858/arpa.2014-0557-oa

Cited by 38 publications

(33 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have shown that histologic grade, ER/PR/HER2 status, and Ki‐67 proliferation index correlate well with RS. () Our data also show that the combination of TNM and biomarker status provides prognostic information comparable to the RS in over 99% of T1‐2N0, ER+/HER2− BCs. Of note, two invasive lobular BCs in the NYULMC cohort were T3N0, histologic grade 2, ER+/HER2− BCs and both had low RS (10 and 5, respectively).…”

Section: Discussionsupporting

confidence: 68%

Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system

et al. 2019

View full text Add to dashboard Cite

The 8th edition of the American Joint Committee on Cancer (AJCC) staging guidelines combine traditional TNM system with biomarkers to reflect our current understanding of tumor biology and targeted therapy. In this study, we investigated the impact of the TNM + Biomarkers staging system and the additive value of Oncotype Dx™ genomic profile recurrence score (RS) (TNM + Biomarkers+RS <11) for the staging of breast cancer (BC) using data from two tertiary referral cancer centers. Compared to TNM alone, the TNM + Biomarkers system changed the stage group in 32.7% of BCs (27% downstage, 5.7% upstage). Most (98.3%) of the downstaged BCs were estrogen receptor (ER)+/progesterone receptor (PR)+, whereas 78% of the upstaged BCs were ER−/PR−/human epidermal growth factor receptor 2 (HER2)−. Compared to TNM + Biomarkers staging, the addition of genetic profile data (TNM + Biomarker+RS <11) downstaged only <1% BCs. Our analysis suggests that for T1‐T2N0 ER+/HER2− BCs, Oncotype Dx™ RS <11 provides added value as a staging parameter only in a very small group of cases compared to TNM + Biomarkers alone.

show abstract

Section: Discussionsupporting

confidence: 68%

Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The lack of a survival benefit from the receipt of adjuvant chemotherapy for early stage ILC observed in our study is also consistent with the known genomic characteristics of this histologic subtype. The 21‐gene RS is predictive of chemotherapy benefit for patients with ER‐positive/HER2‐negative breast cancer . Several studies have evaluated the RS for both IDC and ILC.…”

Section: Discussionmentioning

confidence: 99%

“…The 21-gene RS is predictive of chemotherapy benefit for patients with ERpositive/HER2-negative breast cancer. 19 Several studies have evaluated the RS for both IDC and ILC. In 2 separate, single-center studies that included 108 patients 4 and 120 patients 5 with classical ILC, no patient was categorized in the high-risk group.…”

Section: Value Of Chemotherapy For Ilc and Idc/marmor Et Almentioning

confidence: 99%

Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast

Marmor

Hui

Huang

et al. 2017

Cancer

View full text Add to dashboard Cite

show abstract

“…A number of studies have described the association of the RS with morphologic features and biomarker expression [31–40]. To the best of our knowledge, only one study reported the RS results of special histologic subtypes known to have a favorable prognosis, but the data pertain to only five cases (four MCs and one TC) [39]. …”

Section: Discussionmentioning

confidence: 99%

“…Most MCs (78.8%) in our study had a low RS with a mean RS of 13 ± 6, Although three of thirty-three (9.1%) patients with MC had lymph node micrometastases, the RS was low at ≤11 in all three tumors. The only other study reporting the RS of MC found that three of four MCs had an intermediate RS [39]. Recently, MC with a micropapillary growth pattern in >50% of the tumor has been described as a clinically more aggressive variant of MC with increased rates of lymphatic invasion and regional lymph node metastasis [49].…”

Section: Discussionmentioning

confidence: 99%

The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis

Turashvili

Morrow

Hudis

et al. 2017

Breast Cancer Res Treat

View full text Add to dashboard Cite

Background/purpose The 21-gene recurrence score (RS) assay predicts the likelihood of distant recurrence and chemotherapy benefit in early-stage, estrogen receptor (ER)-positive, HER2-negative breast cancer. Data on the RS of special histologic subtypes of invasive breast carcinoma with favorable prognosis are limited. Methods We reviewed our institutional database to identify patients with special histologic subtypes of breast cancer associated with favorable prognosis and available RS results. Our cohort consists of fifty-seven women: thirty-three patients with pure mucinous carcinoma (MC), ten with tubular carcinoma (TC), nine with encapsulated papillary carcinoma (EPC), and five with solid papillary carcinoma (SPC). Results Most (44/57, 77.2%) carcinomas had low RS (≤17), and none had high RS (≥31). All EPCs had low RS, but other subtypes had RS 18–30. Higher RS was associated with lower progesterone receptor (PR) expression by immunohistochemistry and lower PR mRNA scores (P ≤ 0.007). No morphologic feature (tumor grade, biopsy site changes, cellular stroma, inflammatory cells) was associated with RS ≥ 18. At a median follow-up of 40 months, the distant recurrence-free survival was 100%. One patient with SPC developed locoregional recurrence at 22 months. Conclusions As the largest series to date, our study raises the question of whether the RS assay is necessary for breast cancers with favorable histology. Reflex testing of node-negative, ER+/HER2− breast cancers may be deferred for these special histologic subtypes, emphasizing the need for multidisciplinary discussions between breast pathologists and other members of the breast cancer team.

show abstract

Comparison of Oncotype DX Recurrence Score by Histologic Types of Breast Carcinoma

Cited by 38 publications

References 28 publications

Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system

Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system

Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast

The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis

Contact Info

Product

Resources

About